Several coronavirus vaccines have passed clinical phase 3 trials in the US. If any of these are successful, infectious disease experts posit that things may return to normal around the spring of next year.
Currently, Moderna and Pfizer have made the biggest strides on this front; both pharmaceutical companies have produced doses that evidence a 95% efficacy rate.
The most present challenge for health officials in the meantime is informing clinicians on how to properly administer two vaccine shots at varying intervals.
In the time between shots, some patient samples have reported hang-over like symptoms including headache, nausea, and fatigue. For most, these reactions persist for about a day.
Even the most optimistic about the efficacy rates indexed above are curious about how the nation will react when doses are cleared for the general public. Sill, all measures seem to indicate historic breakthroughs in vaccinology research.
“I would still like to see all of the actual data, but what we’ve seen so far is absolutely remarkable,” says Paul Offit, a vaccine researcher at the Children’s Hospital of Philadelphia who is a member of an independent committee of vaccine experts that advises FDA.
Earlier today, Moderna announced that only 11 people of the 30,000 people featured in their efficacy trial who received two doses of their vaccine candidate, developed COVID-19 symptoms compared to the 185 symptomatic cases reported in a placebo group.
Moreover, no one in the vaccine group developed severe manifestations of COVID-19. The results were not impacted by ethnicity or gender.
“There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group. The company today plans to file a request for emergency use authorization (EUA) for its vaccine with the U.S. Food and Drug Administration (FDA), and is also seeking a similar green light from the European Medicines Agency.” The American Association for the Advancement of Science reports.
This kind of press has afforded public health officials the opportunity to urge populations to come back for a second vaccine shot even if the first one induced a mild-adverse reaction.
Two doses of Moderna’s vaccine reliably prevented clinically recognizable COVID-19 and categorically did so with respect to severe manifestations.
The company plans to administer 20 million vaccine doses to the US government by the end of 2020.
“The company will ask the FDA to review an expanded data set showing the vaccine is 94.1% effective at preventing Covid-19 and 100% effective at preventing severe cases of the disease. The FDA will meet with its advisory committee in December to review Pfizer’s and Moderna’s applications, medical correspondent, Elizabeth Cohen explained. “The first vaccinations in the United States are expected to take place “towards the latter part of December,” according to Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases.”